

# MILLENNIUM LIMITED ACN 133 453 531

Unit 9U 175 Lower Gibbes Street Chatswood NSW 2067

## **Australian Securities Exchange Announcement**

31 July 2020

## WITHDRAWAL OF THE PUBLIC OFFER UNDER THE REPLACEMENT PROSPECTUS DATED 18 MAY 2020

**Millennium Limited** (ASX: MHD) ("**Company**" or "**MHD**") advises that it has withdrawn the offer under the Replacement Prospectus dated 18 May 2020 ("Prospectus").

The Company will apply to ASIC to formally withdraw the Prospectus. The Company thanks those investors who supported the offer and will arrange for all funds received to date to be returned to applicants as soon as practicable.

While there has been considerable interest in Advent Health during the offer period from private and institutional investors, Advent Health will be considering alternative capital raising strategies including from private equity firms. This interest has been driven by:

- the growing demand for allied health services as primary healthcare provision evolves to more holistically provide services focussed on sustained patient well-being;
- continued demand for services through COVID-19 (especially related to working from home injuries and mental health services);
- the majority of vendor businesses have continued to perform well during COVID-19;
- intra-state nature of the businesses with limited impact from state and international boarder closures due to COVID-19;
- business footprint enabling it to capture a larger share of the allied health market; and
- expansion opportunities including its disciplined acquisitions pipeline and improved group operating systems that allow clinicians to focus on integrated services to patients.

The Company's share registry Computershare will refund any subscriptions taken by cheque. Please contact the Company's sponsoring broker Novus Capital if you require a refund of subscriptions made via BPAY.

The Company lodged a Supplementary Prospectus to ASIC today; a copy of the Supplementary Prospectus is attached below.

For any further queries, please contact the Company Secretary on the detail set out below,

Ying Huang Company Secretary yinghuang@millenniumltd.com.au

Wei Huang Chairman

## SUPPLEMENTARY PROSPECTUS

## MILLENNIUM LIMITED ACN 133 453 431

### 1. IMPORTANT INFORMATION

This is a supplementary prospectus (**Supplementary Prospectus**) intended to be read with the replacement prospectus dated 18 May 2020 (**Replacement Prospectus**) which replaced the prospectus dated 13 March 2020 (**Prospectus**), in each case issued by Millennium Limited ACN 133 453 431 (**Company**).

This Supplementary Prospectus is dated 31 July 2020 and was lodged with ASIC on that date. ASIC, ASX and their respective officers take no responsibility for the contents of this Supplementary Prospectus.

This Supplementary Prospectus should be read together with the Prospectus and the Replacement Prospectus. Other than as set out below, all details in relation to the Prospectus and the Replacement Prospectus remain unchanged. Terms and abbreviations defined in the Prospectus and the Replacement Prospectus have the same meaning when used in this Supplementary Prospectus. If there is a conflict between the Prospectus, the Replacement Prospectus and this Supplementary Prospectus, this Supplementary Prospectus will prevail.

This Supplementary Prospectus will be issued with the Prospectus and the Replacement Prospectus as an electronic prospectus, copies of which can be downloaded from the website of the Company at www.adventhealth.com.au.

This is an important document and should be read in its entirety. If you do not understand it, you should consult your professional advisors without delay.

### 2. WITHDRAWAL OF OFFER

The purpose of this Supplementary Prospectus is to notify investors that the Directors of the Company have resolved to withdraw the Offer as set out in the Prospectus and the Replacement Prospectus. This Supplementary Prospectus formally withdraws the Offer. The Company advises that the Offer is now closed and that the timetable for the Offer is no longer in effect. Accordingly, no securities will be issued and the Company will not be accepting any further Applications.

Investors who have applied for and paid for Shares under the Offer will have their Application Monies refunded in full.

The expiry date of the Prospectus (as replaced by the Replacement Prospectus) is brought forward to the date of this Supplementary Prospectus, being 31 July 2020.

### 3. REFUND OF APPLICATION MONIES

All Application Monies received by the Company pursuant to the Prospectus or Replacement Prospectus will be refunded in full.

Application Monies received from clients of the Lead Manager, Novus Capital, will be refunded by the Lead Manager as soon as practicable.

For those Applicants who subscribed for Shares under the Prospectus or Replacement Prospectus directly through the Company's Share Registry, Computershare, payment of the refund will be made by way of cheque to the address set out in the Applicant's respective Application Form. The Company will coordinate with the Share Registry to process all cheques as soon as practicable.

Anyone with questions concerning the refund can contact the Share Registry on 1300 850 505.

## 4. DIRECTORS' AUTHORISATION

This Supplementary Prospectus is issued by the Company and its issue has been authorised by a resolution of the Directors. The Directors believe that the Prospectus when read together with the Replacement Prospectus and this Supplementary Prospectus contains all the information that would be required by sections 710 and 711 of the Corporations Act and does not contain any material statement that is misleading or deceptive.

In accordance with section 720 of the Corporations Act, each Director has consented to the lodgement of this Supplementary Prospectus with ASIC and has not withdrawn that consent prior to lodgement.

Dated 31 July 2020

-

Wei Huang Director